Lv3
310 积分 2024-02-27 加入
Once-weekly semaglutide 2·4 mg in an Asian population with obesity, defined as BMI ≥25 kg/m2, in South Korea and Thailand (STEP 11): a randomised, double-blind, placebo-controlled, phase 3 trial
1个月前
已完结
Tirzepatide for Weight Reduction in Chinese Adults With Obesity
3个月前
已完结
Tirzepatide as Compared with Semaglutide for the Treatment of Obesity
3个月前
已完结
Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity
3个月前
已完结
Tirzepatide for Obesity Treatment and Diabetes Prevention
3个月前
已完结
Tirzepatide adds hepatoprotection to its armoury
1年前
已完结
Effect of tirzepatide versus insulin degludec on liver fat content and abdominal adipose tissue in people with type 2 diabetes (SURPASS-3 MRI): a substudy of the randomised, open-label, parallel-group, phase 3 SURPASS-3 trial
1年前
已完结
皖公网安备34019202002308
